よむ、つかう、まなぶ。
07 参考資料 1－1 百日せきファクトシート［6.8MB］ (40 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_34803.html |
| 出典情報 | 厚生科学審議会 予防接種・ワクチン分科会 予防接種基本方針部会 ワクチン評価に関する小委員会（第20回 8／29）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
Chemother. 2009. 53:3147-9.
54. Warfel JM, Beren J, Kelly VK, Lee G, Merkel TJ. Nonhuman primate model of pertussis.
Infect Immun. 2012. 80:1530-6.
55. Warfel JM, Zimmerman LI, Merkel TJ. Acellular pertussis vaccines protect against disease
but fail to prevent infection and transmission in a nonhuman primate model. Proc Natl
Acad Sci U S A. 2014. 111:787-92.
56. Center for Disease Control and Prevention. FDA approval of expanded age indication for a
tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine. MMWR Morb
Mortal Wkly Rep. 2011. 60:1279-80.
57. Center for Disease Control and Prevention. Updated recommendations for use of tetanus
toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine in adults aged 65
years and older - Advisory Committee on Immunization Practices (ACIP), 2012. MMWR
Morb Mortal Wkly Rep. 2012. 61:468-70.
58. Bassinet L, Matrat M, Njamkepo E, Aberrane S, Housset B, Guiso N. Nosocomial pertussis
outbreak among adult patients and healthcare workers. Infect Control Hosp Epidemiol.
2004. 25:995-7.
59. Calugar A, Ortega-Sanchez IR, Tiwari T, Oakes L, Jahre JA, Murphy TV. Nosocomial
pertussis: costs of an outbreak and benefits of vaccinating health care workers. Clin Infect
Dis. 2006. 42:981-8.
60. Center for Disease Control and Prevention. Outbreaks of pertussis associated with
hospitals--Kentucky, Pennsylvania, and Oregon, 2003. MMWR Morb Mortal Wkly Rep.
2005. 54:67-71.
61. Tanaka H, Kaji M, Higuchi K, Shinohara N, Norimatsu M, Kawazoe H, Ninomiya
M, Fukuoka N, Ishii N, Fujita J, Okabe A, Houchi H. Problems associated with
prophylactic use of erythromycin in 1566 staff to prevent hospital infection during the
outbreak of pertussis. J Clin Pharm Ther. 2009. 34:719-22.
62. 三鴨廣繁, 山岸由佳. 日本における成人百日咳の現状. The Japanese Journal of
Antibiotics. 2012. 65:163-71.
63. Nakamura Y, Kamachi K, Toyoizumi-Ajisaka H, Otsuka N, Saito R, Tsuruoka J, Katsuta
T, Nakajima N, Okada K, Kato T, Arakawa Y. Marked difference between adults and
children in Bordetella pertussis DNA load in nasopharyngeal swabs. Clin Microbiol Infect.
2011. 17:365-70.
64. Mooi FR, van Loo IH, van Gent M, He Q, Bart MJ, Heuvelman KJ, de Greeff
SC, Diavatopoulos D, Teunis P, Nagelkerke N, Mertsola J. Bordetella pertussis strains with
increased toxin production associated with pertussis resurgence. Emerg Infect Dis. 2009.
15:1206-13.
39
54. Warfel JM, Beren J, Kelly VK, Lee G, Merkel TJ. Nonhuman primate model of pertussis.
Infect Immun. 2012. 80:1530-6.
55. Warfel JM, Zimmerman LI, Merkel TJ. Acellular pertussis vaccines protect against disease
but fail to prevent infection and transmission in a nonhuman primate model. Proc Natl
Acad Sci U S A. 2014. 111:787-92.
56. Center for Disease Control and Prevention. FDA approval of expanded age indication for a
tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine. MMWR Morb
Mortal Wkly Rep. 2011. 60:1279-80.
57. Center for Disease Control and Prevention. Updated recommendations for use of tetanus
toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine in adults aged 65
years and older - Advisory Committee on Immunization Practices (ACIP), 2012. MMWR
Morb Mortal Wkly Rep. 2012. 61:468-70.
58. Bassinet L, Matrat M, Njamkepo E, Aberrane S, Housset B, Guiso N. Nosocomial pertussis
outbreak among adult patients and healthcare workers. Infect Control Hosp Epidemiol.
2004. 25:995-7.
59. Calugar A, Ortega-Sanchez IR, Tiwari T, Oakes L, Jahre JA, Murphy TV. Nosocomial
pertussis: costs of an outbreak and benefits of vaccinating health care workers. Clin Infect
Dis. 2006. 42:981-8.
60. Center for Disease Control and Prevention. Outbreaks of pertussis associated with
hospitals--Kentucky, Pennsylvania, and Oregon, 2003. MMWR Morb Mortal Wkly Rep.
2005. 54:67-71.
61. Tanaka H, Kaji M, Higuchi K, Shinohara N, Norimatsu M, Kawazoe H, Ninomiya
M, Fukuoka N, Ishii N, Fujita J, Okabe A, Houchi H. Problems associated with
prophylactic use of erythromycin in 1566 staff to prevent hospital infection during the
outbreak of pertussis. J Clin Pharm Ther. 2009. 34:719-22.
62. 三鴨廣繁, 山岸由佳. 日本における成人百日咳の現状. The Japanese Journal of
Antibiotics. 2012. 65:163-71.
63. Nakamura Y, Kamachi K, Toyoizumi-Ajisaka H, Otsuka N, Saito R, Tsuruoka J, Katsuta
T, Nakajima N, Okada K, Kato T, Arakawa Y. Marked difference between adults and
children in Bordetella pertussis DNA load in nasopharyngeal swabs. Clin Microbiol Infect.
2011. 17:365-70.
64. Mooi FR, van Loo IH, van Gent M, He Q, Bart MJ, Heuvelman KJ, de Greeff
SC, Diavatopoulos D, Teunis P, Nagelkerke N, Mertsola J. Bordetella pertussis strains with
increased toxin production associated with pertussis resurgence. Emerg Infect Dis. 2009.
15:1206-13.
39